

Anika Therapeutics to Present at the Canaccord Genuity Musculoskeletal Conference on February 7

Anika Therapeutics to Present at the Canaccord Genuity Musculoskeletal Conference on February 7 BEDFORD, Mass. --(BUSINESS WIRE)--Feb. 2, 2012-- <u>Anika Therapeutics, Inc.</u> (Nasdaq: ANIK) a leader in products for tissue protection, healing and repair, based on <u>hyaluronic acid</u> ("HA") technology, today announced that Chief Executive Officer Charles H. Sherwood, Ph.D is scheduled to present at the Canaccord Genuity Musculoskeletal Conference in San Francisco.

The live presentation will be webcast at 2:40 p.m. ET / 11:40 a.m. PT on Tuesday, February 7, 2012 and may be accessed via the "Investors" section of Anika's website at www.anikatherapeutics.com. An archive of the presentation also will be available on the website.

About Anika Therapeutics, Inc.

Headquartered in Bedford, Mass., <u>Anika Therapeutics</u>, <u>Inc.</u> develops, manufactures and commercializes therapeutic products for tissue protection, healing, and repair. These products are based on <u>hyaluronic acid</u> (<u>HA</u>), a naturally occurring, biocompatible polymer found throughout the body. Anika's products range from orthopedic/joint health solutions led by <u>Orthovisc</u>®, a treatment for osteoarthritis of the knee; to surgical aids in the <u>ophthalmic</u> and <u>anti-adhesion</u> fields. The company also offers <u>aesthetic dermal fillers</u> for the correction of facial wrinkles. Anika's Italian subsidiary, Anika Therapeutics, S.r.I, provides complementary HA products in orthopedic/joint health and anti-adhesion, as well as therapeutics in new areas such as advanced wound treatment and ear, nose and throat care. Its regenerative tissue technology advances Anika's vision to offer therapeutic products that go beyond pain relief to protect and restore damaged tissue.

Source: Anika Therapeutics, Inc.

Anika Therapeutics, Inc. Charles H. Sherwood, Ph.D., 781-457-9000 CEO or Kevin W. Quinlan, 781-457-9000 CFO

https://ir.anika.com/Anika-Therapeutics-to-Present-at-the-Canaccord-Genuity-Musculoskeletal-Conference-on-February-7